Trevena (Berwyn, PA) a clinical-stage small molecule company focused on G-protein coupled receptor targeting for heart failure and pain, closed a $35M Series B funding from existing investors. Participants include Polaris Venture Partners, New Enterprise Associates, Alta Partners, Healthcare Ventures and Yasuda Enterprise Development Company.

Heptares Therapeutics (United Kingdom) a discovery-stage company focused on small-molecule drugs targeting G-protein-coupled receptors whose lead indication is Parkinson’s, closed a $29.9M Series A financing. Participants include Clarus Ventures, MVM Life Science Partners and Novartis Ventures Option Fund.

Domain Therapeutics (France) and early-stage company focused on the identification of allosteric modulators of G Protein-Coupled Receptors closed a $2.9M Series A financing. Participants include Alsace Inter Regio Fonds d’Investissement, Alsace Création, Sam Eletr and Bernard Gilly. AGF Private Equity, Auriga Partners, Edmond de Rothschild Investment Partners and Sofinnova Partners.

Ascent Therapeutics (Cambridge, MA) early-stage developer of G-protein coupled receptor target modulator therapeutics, closed a $19M Series A financing. Participants include Novartis Option Fund, Healthcare Ventures and TVM Capital.